Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 4
Submit an article Journal homepage
161
Views
0
CrossRef citations to date
0
Altmetric
Review

Advances in Adoptive Immunotherapy to Accelerate T-Cellular Immune Reconstitution After Hla-Incompatible Hematopoietic Stem Cell Transplantation

Christian Reimann1 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France: Département de Biothérapie, Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, 75015Paris, FranceView further author information
,
Liliane Dal Cortivo2 Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Paris, FranceView further author information
,
Salima Hacein-Bey-Abina2 Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Paris, France;3 Université Paris Descartes, Paris, FranceView further author information
,
Alain Fischer1 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France: Département de Biothérapie, Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, 75015Paris, France;2 Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Paris, France;3 Université Paris Descartes, Paris, FranceView further author information
,
Isabelle André-Schmutz1 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France: Département de Biothérapie, Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, 75015Paris, France;3 Université Paris Descartes, Paris, FranceView further author information
&
Marina Cavazzana-Calvo1 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France: Département de Biothérapie, Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, 75015Paris, France;2 Hopital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Paris, France;3 Université Paris Descartes, Paris, FranceCorrespondence[email protected]
View further author information
Pages 481-496 | Published online: 16 Jul 2010

Bibliography

  • Cavazzana-Calvo M , LagresleC, Hacein-Bey-AbinaS, FischerA: Gene therapy for severe combined immunodeficiency.Annu. Rev. Med.56 , 585–602 (2005).
  • Gaspar HB , ParsleyKL, HoweSet al.: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gretroviral vector.Lancet364 , 2181–2187 (2004).
  • Neven B , LeroyS, DecaluweHet al.: Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency.Blood113 , 4114–4124 (2009).
  • Cavazzana-Calvo M , CarlierF, Le Deist F et al.: Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood109 , 4575–4581 (2007).
  • Muller SM , KohnT, SchulzAS, DebatinKM, FriedrichW: Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation.Blood96 , 4344–4349 (2000).
  • Chen BJ , CuiX, LiuC, ChaoNJ: Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.Blood99 , 3083–3088 (2002).
  • Fehse B , FrerkO, GoldmannM, BuldukM, ZanderAR: Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).Br. J. Haematol.109 , 644–651 (2000).
  • Hartwig UF , NonnM, KhanS, MeyerRG, HuberC, HerrW: Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.Bone Marrow Transplant.37 , 297–305 (2006).
  • Koh MB , PrenticeHG, LowdellMW: Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.Bone Marrow Transplant.23 , 1071–1079 (1999).
  • Samarasinghe S , MancaoC, PuleMet al.: Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.Blood115 , 396–407 (2010).
  • Solomon SR , MielkeS, SavaniBNet al.: Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.Blood106 , 1123–1129 (2005).
  • Hartwig UF , RobbersM, WickenhauserC, HuberC: Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.Blood99 , 3041–3049 (2002).
  • Solomon SR , TranT, CarterCSet al.: Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.Cytotherapy4 , 395–406 (2002).
  • Wehler TC , NonnM, BrandtBet al.: Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.Blood109 , 365–373 (2007).
  • Godfrey WR , KrampfMR, TaylorPA, BlazarBR: ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation.Blood103 , 1158–1165 (2004).
  • Cavazzana-Calvo M , FromontC, Le Deist F et al.: Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation50 , 1–7 (1990).
  • Koh MB , PrenticeHG, CorboM, MorganM, CotterFE, LowdellMW: Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment.Br. J. Haematol.118 , 108–116 (2002).
  • Amrolia PJ , Muccioli-CasadeiG, YvonEet al.: Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.Blood102 , 2292–2299 (2003).
  • Fehse B , GoldmannM, FrerkO, BuldukM, ZanderAR: Depletion of alloreactive donor T cells using immunomagnetic cell selection.Bone Marrow Transplant.25(Suppl. 2) , S39–S42 (2000).
  • Andre-Schmutz I , Le Deist F, Hacein-Bey-Abina S et al.: Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a Phase 1/2 study. Lancet360 , 130–137 (2002).
  • Amrolia PJ , Muccioli-CasadeiG, HulsHet al.: Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.Blood108 , 1797–1808 (2006).
  • Edinger M , HoffmannP, ErmannJet al.: CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.Nat. Med.9 , 1144–1150 (2003).
  • Taylor PA , LeesCJ, BlazarBR: The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.Blood99 , 3493–3499 (2002).
  • Mielke S , RezvaniK, SavaniBNet al.: Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.Blood110 , 1689–1697 (2007).
  • Guimond M , BalassyA, BarretteM, BrochuS, PerreaultC, RoyDC: P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.Blood100 , 375–382 (2002).
  • Roy DC , BusqueL, FishDet al.: Phase I clinical study of donor lymphocyte infusion depleted of alloreactive T cells after haplotype mismatched myeloablative stem cell transplantation to limit infections and malignant relapse without causing GvHD.Blood108 , 309 (2006).
  • Schwarer AP , JiangYZ, BrookesPAet al.: Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation.Lancet341 , 203–205 (1993).
  • Mielke S , NunesR, RezvaniKet al.: A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.Blood111 , 4392–4402 (2008).
  • Perruccio K , TopiniF, TostiAet al.: Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.Blood Cells Mol. Dis.40 , 76–83 (2008).
  • Perruccio K TF, Tosti A, Carotti A, Aloisi F, Aversa F: Adoptive immunotherapy after haploidentical stem cell transplantation with T-cells allodepleted by photodynamic purging. Bone Marrow Transplant.41 , S24–S25 (2008) (Abstract 172).
  • Andre-Schmutz I , Dal Cortivo L, Fischer A, Cavazzana-Calvo M: Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation. Cytotherapy7 , 102–108 (2005).
  • Riddell SR , WatanabeKS, GoodrichJM, LiCR, AghaME, GreenbergPD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.Science257 , 238–241 (1992).
  • Walter EA , GreenbergPD, GilbertMJet al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.N. Engl. J. Med.333 , 1038–1044 (1995).
  • Heslop HE , NgCY, LiCet al.: Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.Nat. Med.2 , 551–555 (1996).
  • Rooney CM , SmithCA, NgCYet al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients.Blood92 , 1549–1555 (1998).
  • Beck O , ToppMS, KoehlUet al.: Generation of highly purified and functionally active human Th1 cells against Aspergillus fumigatus.Blood107 , 2562–2569 (2006).
  • Tramsen L , KoehlU, TonnTet al.: Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.Bone Marrow Transplant.43 , 13–19 (2009).
  • Li Pira G , KappM, MancaF, EinseleH: Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host.Curr. Opin. Immunol.21 , 549–556 (2009).
  • Hamel Y , BlakeN, GabrielssonSet al.: Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein–Barr virus EBNA3C protein: a novel approach for immunotherapy.Hum. Gene Ther.13 , 855–866 (2002).
  • Leen AM , MyersGD, SiliUet al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.Nat. Med.12 , 1160–1166 (2006).
  • Leen AM , ChristinA, MyersGDet al.: Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplantation.Blood114 , 4283–4292 (2009).
  • Fry TJ , MackallCL: Interleukin-7 and immunorestoration in HIV: beyond the thymus.J. Hematother. Stem Cell Res.11 , 803–807 (2002).
  • Fry TJ , MackallCL: Interleukin-7: from bench to clinic.Blood99 , 3892–3904 (2002).
  • Watanabe M , UenoY, YajimaTet al.: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes.J. Clin. Invest.95 , 2945–2953 (1995).
  • Puel A , ZieglerSF, BuckleyRH, LeonardWJ: Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.Nat. Genet.20 , 394–397 (1998).
  • Mackall CL , FryTJ, BareC, MorganP, GalbraithA, GressRE: IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation.Blood97 , 1491–1497 (2001).
  • Parkman R , WeinbergKI: Immunological reconstitution following bone marrow transplantation.Immunol. Rev.157 , 73–78 (1997).
  • Fry TJ , ChristensenBL, KomschliesKL, GressRE, MackallCL: Interleukin-7 restores immunity in athymic T-cell-depleted hosts.Blood97 , 1525–1533 (2001).
  • Alpdogan O , MuriglanSJ, EngJMet al.: IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation.J. Clin. Invest.112 , 1095–1107 (2003).
  • Broers AE , Posthumus-van Sluijs SJ, Spits H et al.: Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants. Blood102 , 1534–1540 (2003).
  • Shultz LD , LyonsBL, BurzenskiLMet al.: Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R g null mice engrafted with mobilized human hemopoietic stem cells.J. Immunol.174 , 6477–6489 (2005).
  • Storek J , GillespyT 3rd, Lu H et al.: Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. Blood101 , 4209–4218 (2003).
  • Fry TJ , MoniuszkoM, CreekmoreSet al.: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.Blood101 , 2294–2299 (2003).
  • Beq S , NugeyreMT, Ho Tsong Fang R et al.: IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J. Immunol.176 , 914–922 (2006).
  • Sportes C , HakimFT, MemonSAet al.: Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.J. Exp. Med.205 , 1701–1714 (2008).
  • Sportes C , BabbRR, KrumlaufMCet al.: Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.Clin. Cancer Res.16 , 727–735.
  • Dean RM , FryT, MackallCet al.: Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.J. Clin. Oncol.26 , 5735–5741 (2008).
  • Sinha ML , FryTJ, FowlerDH, MillerG, MackallCL: Interleukin 7 worsens graft-versus-host disease.Blood100 , 2642–2649 (2002).
  • Andre-Schmutz I , BonhommeD, YatesFet al.: IL-7 effect on immunological reconstitution after HSCT depends on MHC incompatibility.Br. J. Haematol.126 , 844–851 (2004).
  • Chen Q , KhouryM, ChenJ: Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice.Proc. Natl Acad. Sci. USA106 , 21783–21788 (2009).
  • Huntington ND , LegrandN, AlvesNLet al.: IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.J. Exp. Med.206 , 25–34 (2009).
  • Williams KM , HakimFT, GressRE: T cell immune reconstitution following lymphodepletion.Semin. Immunol.19 , 318–330 (2007).
  • Alpdogan O , van den Brink MR: IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol.26 , 56–64 (2005).
  • Alpdogan O , EngJM, MuriglanSJet al.: Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.Blood105 , 865–873 (2005).
  • Klebanoff CA , FinkelsteinSE, SurmanDRet al.: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.Proc. Natl Acad. Sci. USA101 , 1969–1974 (2004).
  • Danilenko DM , MontestruqueS, PhiloJSet al.: Recombinant rat fibroblast growth factor-16: structure and biological activity.Arch. Biochem. Biophys.361 , 34–46 (1999).
  • Farrell CL , BreadyJV, RexKLet al.: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.Cancer Res.58 , 933–939 (1998).
  • Min D , Panoskaltsis-MortariA, KuroOM, HollanderGA, BlazarBR, WeinbergKI: Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging.Blood109 , 2529–2537 (2007).
  • Seggewiss R , LoreK, GuenagaFJet al.: Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques.Blood110 , 441–449 (2007).
  • Jenq RR , KingCG, VolkCet al.: Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.Blood113 , 1574–1580 (2009).
  • Spielberger R , StiffP, BensingerWet al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers.N. Engl. J. Med.351 , 2590–2598 (2004).
  • Stiff PJ , EmmanouilidesC, BensingerWIet al.: Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.J. Clin. Oncol.24 , 5186–5193 (2006).
  • Mackall CL , GressRE: Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy.Immunol. Rev.157 , 61–72 (1997).
  • Utsuyama M , HirokawaK: Hypertrophy of the thymus and restoration of immune functions in mice and rats by gonadectomy.Mech. Ageing Dev.47 , 175–185 (1989).
  • Medina KL , StrasserA, KincadePW: Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors.Blood95 , 2059–2067 (2000).
  • Dudakov JA , GoldbergGL, ReisegerJJ, VlahosK, ChidgeyAP, BoydRL: Sex steroid ablation enhances hematopoietic recovery following cytotoxic antineoplastic therapy in aged mice.J. Immunol.183 , 7084–7094 (2009).
  • Goldberg GL , SutherlandJS, HammetMVet al.: Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation.Transplantation80 , 1604–1613 (2005).
  • Goldberg GL , AlpdoganO, MuriglanSJet al.: Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation.J. Immunol.178 , 7473–7484 (2007).
  • Goldberg GL , KingCG, NejatRAet al.: Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation.J. Immunol.182 , 5846–5854 (2009).
  • Kelly RM , HighfillSL, Panoskaltsis-MortariAet al.: Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.Blood111 , 5734–5744 (2008).
  • Sutherland JS , GoldbergGL, HammettMVet al.: Activation of thymic regeneration in mice and humans following androgen blockade.J. Immunol.175 , 2741–2753 (2005).
  • Sutherland JS , SpyroglouL, MuirheadJLet al.: Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade.Clin. Cancer Res.14 , 1138–1149 (2008).
  • Clark R : The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function.Endocr. Rev.18 , 157–179 (1997).
  • Montecino-Rodriguez E , ClarkR, DorshkindK: Effects of insulin-like growth factor administration and bone marrow transplantation on thymopoiesis in aged mice.Endocrinology139 , 4120–4126 (1998).
  • Murphy WJ , DurumSK, LongoDL: Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice.Proc. Natl Acad. Sci. USA89 , 4481–4485 (1992).
  • Hanley MB , NapolitanoLA, McCuneJM: Growth hormone-induced stimulation of multilineage human hematopoiesis.Stem Cells23 , 1170–1179 (2005).
  • Huang S , TerstappenLW: Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38- hematopoietic stem cells.Blood83 , 1515–1526 (1994).
  • Chu YW , SchmitzS, ChoudhuryBet al.: Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.Blood112 , 2836–2846 (2008).
  • Alpdogan O , MuriglanSJ, KappelBJet al.: Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation.Transplantation75 , 1977–1983 (2003).
  • Robbins K , McCabeS, ScheinerT, StrasserJ, ClarkR, JardieuP: Immunological effects of insulin-like growth factor-I – enhancement of immunoglobulin synthesis.Clin. Exp. Immunol.95 , 337–342 (1994).
  • Tian ZG , WoodyMA, SunRet al.: Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice.Stem Cells16 , 193–199 (1998).
  • Napolitano LA , SchmidtD, GotwayMBet al.: Growth hormone enhances thymic function in HIV-1-infected adults.J. Clin. Invest.118 , 1085–1098 (2008).
  • Ma NS , ShahAJ, GeffnerME, KapoorN: IGF-I stimulates in vivo thymopoiesis after stem cell transplantation in a child with Omenn syndrome.J. Clin. Immunol.30 , 114–120.
  • Schmitt TM , Zuniga-PfluckerJC: Induction of T cell development from hematopoietic progenitor cells by Delta-like-1 in vitro.Immunity17 , 749–756 (2002).
  • Ohishi K , Varnum-FinneyB, BernsteinID: δ-1 enhances marrow and thymus repopulating ability of human CD34+ CD38- cord blood cells.J. Clin. Invest.110 , 1165–1174 (2002).
  • Radtke F , WilsonA, ManciniSJ, MacDonaldHR: Notch regulation of lymphocyte development and function.Nat. Immunol.5 , 247–253 (2004).
  • Wolfer A , WilsonA, NemirM, MacDonaldHR, RadtkeF: Inactivation of Notch1 impairs VDJβ rearrangement and allows pre-TCR-independent survival of early α β lineage thymocytes.Immunity16 , 869–879 (2002).
  • Ciofani M , Zuniga-PfluckerJC: Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism.Nat. Immunol.6 , 881–888 (2005).
  • Schmitt TM , CiofaniM, PetrieHT, Zuniga-PfluckerJC: Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions.J. Exp. Med.200 , 469–479 (2004).
  • Pui JC , AllmanD, XuLet al.: Notch1 expression in early lymphopoiesis influences B versus T lineage determination.Immunity11 , 299–308 (1999).
  • Jaleco AC , NevesH, HooijbergEet al.: Differential effects of Notch ligands δ-1 and Jagged-1 in human lymphoid differentiation.J. Exp. Med.194 , 991–1002 (2001).
  • De Smedt M , HoebekeI, PlumJ: Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment.Blood Cells Mol. Dis.33 , 227–232 (2004).
  • La Motte-Mohs RN , HererE, Zuniga-PfluckerJC: Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro.Blood105 , 1431–1439 (2005).
  • Zuniga-Pflucker JC : T-cell development made simple.Nat. Rev. Immunol.4 , 67–72 (2004).
  • Watanabe Y , MazdaO, AibaYet al.: A murine thymic stromal cell line which may support the differentiation of CD4–8- thymocytes into CD4+8- α β T cell receptor positive T cells.Cell Immunol.142 , 385–397 (1992).
  • Zakrzewski JL , KochmanAA, LuSXet al.: Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.Nat. Med.12 , 1039–1047 (2006).
  • Zakrzewski JL , SuhD, MarkleyJCet al.: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.Nat. Biotechnol.26 , 453–461.
  • Meek B , CloosenS, BorsottiCet al.: In vitro-differentiated T/natural killer-cell progenitors derived from human CD34+ cells mature in the thymus.Blood115 , 261–264 (2008).
  • Lefort N , BenneC, LelievreJDet al.: Short exposure to Notch ligand δ-4 is sufficient to induce T-cell differentiation program and to increase the T cell potential of primary human CD34+ cells.Exp. Hematol.34 , 1720–1729 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.